January 17-19, 2024, PST, the 5th International Conference on Base Editing, Prime Editing & Related Enzymes will be held at San Diego, California. The primary goal of this conference is to bring together investigators interested in base editing enzymes, predominantly APOBEC and ADAR deaminase family members but also other promising enzymes, and discuss ways to harness their activities toward editing for beneficial purposes. Topics will range from fundamental biology to translational and applied applications and include studies on all kingdoms of life. Speakers and participants will represent both academic and commercial interests. An additional goal will be providing an exceptionally comfortable and stimulating atmosphere for the cultivation of new and cross-disciplinary collaborations and ideas and discussions of the rapidly expanding editing field.
Dr. Jia Chen, Professor of ShanghaiTech University, Co-founder of CorrectSequence Therapeutics will participate in this conference and give an oral presentation titled” Therapeutic base editing for β-thalassemia” on Jan. 17, at 5:05 - 5:20 pm, PST.
The speakers:
David Liu, Broad Institute, Harvard University, HHMI, USA
Reilly Mach, Scripps Research Institute, USA
Jia Chen, ShanghaiTech University, China
Mallory Evanoff, University of California San Diego, USA
Andrew Bellinger, Verve Therapeutics, USA
Mark Osborn, University of Minnesota, USA
Peter Chen, Prime Medicine, USA
……
For more information about the conference, visit: https://cancerresearch.uci.edu/seminars-and-events/deaminet/
About CorrectSequence Therapeutics
CorrectSequence TherapeuticsTM (CorrectseqTM) (www.correctsequence.com) aims to use our innovative gene editing technology to help people with severe diseases.
The gene editing systems under in-house development in Correctseq towards medical applications are licensed in from ShanghaiTech University with global exclusive rights. The transformer Base Editing (tBE) system with the best safety and efficacy performance is currently applied in all the IND enabling pipelines. The research work of base editing systems was published in high-profile scientific journals including Nature Biotechnology, Nature Cell Biology, Nature Structural & Molecular Biology, Cell Research and Cell Reports.
Our goal is to discover, develop, manufacture, and commercialize curative genetic medicines for various diseases. Multiple pipelines for genetic diseases, cancer immunotherapy, metabolic diseases, infectious diseases are well underway. We are also working on novel target screening for tBE editing in ophthalmology and neurological diseases. We have set up R&D, CMC and cGMP manufacturing platforms for ex vivo and in vivo treatment strategies to facilitate translation and application of our innovative research. The industrial standard research and CMC platform could provide efficient, reliable, and safe solutions for unmet medical needs.
